Hyperfractionated radiation therapy improves local-regional control, no increase in late toxicity for patients with head and neck cancer
Fairfax, Va., May 1, 2014—Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). This study, “Final Results of Local-Regional Control and